{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:57:13Z","timestamp":1762459033067,"version":"build-2065373602"},"reference-count":78,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,1,5]],"date-time":"2015-01-05T00:00:00Z","timestamp":1420416000000},"content-version":"vor","delay-in-days":703,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.jbo.2012.12.001","type":"journal-article","created":{"date-parts":[[2012,12,31]],"date-time":"2012-12-31T23:28:24Z","timestamp":1356996504000},"page":"38-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Oral care and the use of bone-targeted agents in patients with metastatic cancers: A practical guide for dental surgeons and oncologists"],"prefix":"10.1016","volume":"2","author":[{"given":"Iryna","family":"Kuchuk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasha","family":"Mazzarello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Butterfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Appleton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina L.","family":"Addison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Clemons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbo.2012.12.001_bib1","first-page":"1","article-title":"A systematic review of the role of bisphosphonates in metastatic disease","volume":"8","author":"Ross","year":"2004","journal-title":"Health Technology Assessment (Winchester, England)"},{"key":"10.1016\/j.jbo.2012.12.001_bib2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3109\/13697137.2010.529966","article-title":"Managing bone health with zoledronic acid: a review of randomized clinical study results","volume":"14","author":"Hadji","year":"2011","journal-title":"Climacteric: The Journal of the International Menopause Society"},{"key":"10.1016\/j.jbo.2012.12.001_bib3","doi-asserted-by":"crossref","first-page":"158","DOI":"10.12968\/hmed.2008.69.3.28753","article-title":"Bisphosphonate-related osteochemonecrosis of the jaws","volume":"69","author":"Hegarty","year":"2008","journal-title":"British Journal of Hospital Medicine (London, England: 2005)"},{"key":"10.1016\/j.jbo.2012.12.001_bib4","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0035-1768(06)77081-4","article-title":"Bisphosphonates and maxillo-mandibular osteo(chemo)necrosis","volume":"107","author":"Magremanne","year":"2006","journal-title":"Revue de Stomatologie et de Chirurgie Maxillo-faciale"},{"key":"10.1016\/j.jbo.2012.12.001_bib5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1747-4477.2009.00213.x","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw-2009 update","volume":"35","author":"Ruggiero","year":"2009","journal-title":"Australian Endodontic Journal: The Journal of the Australian Society of Endodontology Inc."},{"issue":"181\u2013203","key":"10.1016\/j.jbo.2012.12.001_bib6","first-page":"4","article-title":"Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) therapy. A critical review","volume":"59","author":"Vescovi","year":"2010","journal-title":"Minerva Stomatologica"},{"key":"10.1016\/j.jbo.2012.12.001_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/jop.2006.2.1.7","article-title":"Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer","volume":"2","author":"Ruggiero","year":"2006","journal-title":"Journal of Oncology Practice\/American Society of Clinical Oncology"},{"key":"10.1016\/j.jbo.2012.12.001_bib8","doi-asserted-by":"crossref","unstructured":"Outcomes of bisphosphonate-related osteonecrosis of the jaw\u2014importance of staging and management guidelines: a large single institutional update. Abstract no. 20526; 2008.","DOI":"10.1200\/jco.2008.26.15_suppl.20526"},{"key":"10.1016\/j.jbo.2012.12.001_bib9","doi-asserted-by":"crossref","first-page":"0","DOI":"10.4414\/smw.2012.13605","article-title":"Osteopathology of the jaw associated with bone resorption inhibitors: what have we learned in the last 8 years?","volume":"142","author":"Jacobsen","year":"2012","journal-title":"Swiss Medical Weekly"},{"key":"10.1016\/j.jbo.2012.12.001_bib10","first-page":"515","article-title":"Bisphosphonate complications including osteonecrosis of the jaw","volume":"356\u201360","author":"Mehrotra","year":"2006","journal-title":"Hematology\/The Education Program of the American Society of Hematology American Society of Hematology Education Program"},{"key":"10.1016\/j.jbo.2012.12.001_bib11","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1345\/aph.1H521","article-title":"Bisphosphonate-induced osteonecrosis of the jaw","volume":"41","author":"Krueger","year":"2007","journal-title":"The Annals of Pharmacotherapy"},{"key":"10.1016\/j.jbo.2012.12.001_bib12","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ejso.2009.12.003","article-title":"Bisphosphonate induced osteonecrosis of the jaw masquerading as tumor: a word of caution for oral surgeons and oncologists","volume":"36","author":"Chaturvedi","year":"2010","journal-title":"European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology"},{"key":"10.1016\/j.jbo.2012.12.001_bib13","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research"},{"key":"10.1016\/j.jbo.2012.12.001_bib14","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1034\/j.1600-0722.2003.00067.x","article-title":"Ultrastructural and histochemical examination of alveolar bone at the pressure areas of rat molars submitted to continuous orthodontic force","volume":"111","author":"Bonafe-Oliveira","year":"2003","journal-title":"European Journal of Oral Sciences"},{"key":"10.1016\/j.jbo.2012.12.001_bib15","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/oxfordjournals.jmicro.a023623","article-title":"Bone wound healing after maxillary molar extraction in ovariectomized aged rats","volume":"47","author":"Shimizu","year":"1998","journal-title":"Journal of Electron Microscopy"},{"key":"10.1016\/j.jbo.2012.12.001_bib16","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.1016\/S8756-3282(96)00138-X","article-title":"Growth factors for bone growth and repair: IGF, TGF beta and BMP","volume":"19","author":"Linkhart","year":"1996","journal-title":"Bone"},{"key":"10.1016\/j.jbo.2012.12.001_bib17","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/ncponc1000","article-title":"Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle","volume":"4","author":"Bertoldo","year":"2007","journal-title":"Nature Clinical Practice Oncology"},{"key":"10.1016\/j.jbo.2012.12.001_bib18","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/edrv.19.1.0325","article-title":"Bisphosphonates: mechanisms of action","volume":"19","author":"Fleisch","year":"1998","journal-title":"Endocrine Reviews"},{"key":"10.1016\/j.jbo.2012.12.001_bib19","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(06)70726-4","article-title":"Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment","volume":"7","author":"Migliorati","year":"2006","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.jbo.2012.12.001_bib20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1756-8722-5-56","article-title":"Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw","volume":"5","author":"Vincenzi","year":"2012","journal-title":"Journal of Hematology & Oncology"},{"key":"10.1016\/j.jbo.2012.12.001_bib21","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","article-title":"Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid","volume":"302","author":"Wood","year":"2002","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.jbo.2012.12.001_bib22","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1177\/0022034511420430","article-title":"A role of oral bacteria in bisphosphonate-induced osteonecrosis of the jaw","volume":"90","author":"Mawardi","year":"2011","journal-title":"Journal of Dental Research"},{"key":"10.1016\/j.jbo.2012.12.001_bib23","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s00428-007-0516-2","article-title":"Actinomycosis of the jaws\u2014histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis","volume":"451","author":"Hansen","year":"2007","journal-title":"Virchows Archiv: An International Journal of Pathology"},{"key":"10.1016\/j.jbo.2012.12.001_bib24","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.14219\/jada.archive.2009.0049","article-title":"Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy","volume":"140","author":"Sedghizadeh","year":"2009","journal-title":"Journal of the American Dental Association (1939)"},{"key":"10.1016\/j.jbo.2012.12.001_bib25","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/0022034510397196","article-title":"Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN","volume":"90","author":"Barasch","year":"2011","journal-title":"Journal of Dental Research"},{"key":"10.1016\/j.jbo.2012.12.001_bib26","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1177\/0022034510387795","article-title":"ONJ in two dental practice-based research network regions","volume":"90","author":"Fellows","year":"2011","journal-title":"Journal of Dental Research"},{"key":"10.1016\/j.jbo.2012.12.001_bib27","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s00432-010-0907-7","article-title":"Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases","volume":"136","author":"Filleul","year":"2010","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"10.1016\/j.jbo.2012.12.001_bib28","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","volume":"23","author":"Hoff","year":"2008","journal-title":"Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research"},{"key":"10.1016\/j.jbo.2012.12.001_bib29","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.jbo.2012.12.001_bib30","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","article-title":"Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia","volume":"65","author":"Mavrokokki","year":"2007","journal-title":"Journal of Oral and Maxillofacial Surgery: Official journal of the American Association of Oral and Maxillofacial Surgeons"},{"key":"10.1016\/j.jbo.2012.12.001_bib31","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.jbo.2012.12.001_bib32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.joms.2009.01.003","article-title":"Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies","volume":"67","author":"Assael","year":"2009","journal-title":"Journal of Oral and Maxillofacial Surgery: Official Journal of the American Association of Oral and Maxillofacial Surgeons"},{"key":"10.1016\/j.jbo.2012.12.001_bib33","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","author":"Saad","year":"2011","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology\/ESMO"},{"key":"10.1016\/j.jbo.2012.12.001_bib34","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/COC.0b013e3182155fcb","article-title":"A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates","volume":"35","author":"Thumbigere-Math","year":"2012","journal-title":"American Journal of Clinical Oncology"},{"key":"10.1016\/j.jbo.2012.12.001_bib35","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.joms.2010.05.043","article-title":"Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates","volume":"68","author":"Lazarovici","year":"2010","journal-title":"Journal of Oral and Maxillofacial Surgery: Official Journal of the American Association of Oral and Maxillofacial Surgeons"},{"key":"10.1016\/j.jbo.2012.12.001_bib36","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1210\/jc.2006-2036","article-title":"Possible association between diabetes and bisphosphonate-related jaw osteonecrosis","volume":"92","author":"Khamaisi","year":"2007","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.jbo.2012.12.001_bib37","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment","volume":"63","author":"Marx","year":"2005","journal-title":"Journal of Oral and Maxillofacial Surgery: Official Journal of the American Association of Oral and Maxillofacial Surgeons"},{"key":"10.1016\/j.jbo.2012.12.001_bib38","doi-asserted-by":"crossref","first-page":"887","DOI":"10.14219\/jada.archive.2010.0288","article-title":"Osteonecrosis of the jaws is associated with high-dose bisphosphonate treatment in patients with cancer","volume":"141","author":"Zahrowski","year":"2010","journal-title":"Journal of the American Dental Association (1939)"},{"key":"10.1016\/j.jbo.2012.12.001_bib39","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.jbo.2012.12.001_bib40","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/07357900802208608","article-title":"Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents","volume":"27","author":"Aragon-Ching","year":"2009","journal-title":"Cancer Investigation"},{"key":"10.1016\/j.jbo.2012.12.001_bib41","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","article-title":"Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer","volume":"122","author":"Guarneri","year":"2010","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.1016\/j.jbo.2012.12.001_bib42","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.2146\/ajhp080251","article-title":"Risk of osteonecrosis of the jaw in cancer patients taking bisphosphonates","volume":"66","author":"Gebara","year":"2009","journal-title":"American Journal of Health-system Pharmacy: AJHP: Official Journal of the American Society of Health-System Pharmacists"},{"key":"10.1016\/j.jbo.2012.12.001_bib43","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00520-010-0882-1","article-title":"A systematic review of bisphosphonate osteonecrosis (BON) in cancer","volume":"18","author":"Migliorati","year":"2010","journal-title":"Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer"},{"key":"10.1016\/j.jbo.2012.12.001_bib44","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology\/ESMO"},{"key":"10.1016\/j.jbo.2012.12.001_bib45","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/annonc\/mdn526","article-title":"Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan","volume":"20","author":"Ripamonti","year":"2009","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology\/ESMO"},{"key":"10.1016\/j.jbo.2012.12.001_bib46","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.breast.2009.07.001","article-title":"Bisphosphonate-associated osteonecrosis of the jaw in breast cancer patients: recommendations for prevention and treatment","volume":"18","author":"Fehm","year":"2009","journal-title":"Breast"},{"key":"10.1016\/j.jbo.2012.12.001_bib47","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/sj.leu.2404682","article-title":"A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma","volume":"21","author":"Corso","year":"2007","journal-title":"Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK"},{"key":"10.1016\/j.jbo.2012.12.001_bib48","doi-asserted-by":"crossref","first-page":"9005","DOI":"10.1200\/jco.2012.30.15_suppl.9005","article-title":"ZOOM: A prospective, randomized trial of zoledronic acid (ZOL; q 4 wk vs. q 12 wk) for long-term treatment in patients with bone-metastatic breast cancer (BC) after 1yr of standard ZOL treatment","volume":"30","author":"Amadori","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jbo.2012.12.001_bib49","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1080\/10428190802483778","article-title":"Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates","volume":"49","author":"Montefusco","year":"2008","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.jbo.2012.12.001_bib50","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1016\/j.joms.2011.02.059","article-title":"Perioperative antibiotic regimen in rats treated with pamidronate plus dexamethasone and subjected to dental extraction: a study of the changes in the jaws","volume":"69","author":"Lopez-Jornet","year":"2011","journal-title":"Journal of Oral and Maxillofacial Surgery: Official Journal of the American Association of Oral and Maxillofacial Surgeons"},{"key":"10.1016\/j.jbo.2012.12.001_bib51","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.joms.2007.08.003","article-title":"Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment","volume":"65","author":"Marx","year":"2007","journal-title":"Journal of Oral and Maxillofacial Surgery: Official Journal of the American Association of Oral and Maxillofacial Surgeons"},{"key":"10.1016\/j.jbo.2012.12.001_bib52","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.joms.2009.02.004","article-title":"Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws","volume":"67","author":"Kunchur","year":"2009","journal-title":"Journal of Oral and Maxillofacial Surgery: official journal of the American Association of Oral and Maxillofacial Surgeons"},{"key":"10.1016\/j.jbo.2012.12.001_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.joms.2011.12.028","article-title":"Serum N-telopeptide and bone-specific alkaline phosphatase levels in patients with osteonecrosis of the jaw receiving bisphosphonates for bone metastases","author":"Morris","year":"2012","journal-title":"Journal of Oral and Maxillofacial Surgery: Official Journal of the American Association of Oral and Maxillofacial Surgeons"},{"key":"10.1016\/j.jbo.2012.12.001_bib54","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s10103-011-0974-2","article-title":"Bisphosphonate-related osteonecrosis: laser-assisted surgical treatment or conventional surgery?","volume":"26","author":"Atalay","year":"2011","journal-title":"Lasers in Medical Science"},{"key":"10.1016\/j.jbo.2012.12.001_bib55","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1086\/648075","article-title":"Bisphosphonate-related osteonecrosis of the jaw: the role of actinomyces","volume":"49","author":"Naik","year":"2009","journal-title":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America"},{"key":"10.1016\/j.jbo.2012.12.001_bib56","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/lary.20076","article-title":"Bisphosphonate-related osteonecrosis of the jaw and its associated risk factors: a Belgian case series","volume":"119","author":"Saussez","year":"2009","journal-title":"The Laryngoscope"},{"key":"10.1016\/j.jbo.2012.12.001_bib57","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.joms.2008.11.015","article-title":"Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients","volume":"67","author":"Lazarovici","year":"2009","journal-title":"Journal of Oral and Maxillofacial Surgery: Official Journal of the American Association of Oral and Maxillofacial Surgeons"},{"key":"10.1016\/j.jbo.2012.12.001_bib58","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.4065\/81.8.1100","article-title":"Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy","volume":"81","author":"Kademani","year":"2006","journal-title":"Mayo Clinic Proceedings Mayo Clinic"},{"key":"10.1016\/j.jbo.2012.12.001_bib59","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.joms.2009.01.006","article-title":"The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws","volume":"67","author":"Carlson","year":"2009","journal-title":"Journal of Oral and Maxillofacial Surgery: Official Journal of the American Association of Oral and Maxillofacial Surgeons"},{"key":"10.1016\/j.jbo.2012.12.001_bib60","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.tripleo.2010.04.015","article-title":"The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw","volume":"111","author":"Wilde","year":"2011","journal-title":"Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics"},{"key":"10.1016\/j.jbo.2012.12.001_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcms.2012.01.005","article-title":"Surgical treatment of bisphosphonate-associated osteonecrosis of the jaw: Technical report and follow up of 21 patients","author":"Voss","year":"2012","journal-title":"Journal of Cranio-maxillo-facial Surgery: Official Publication of the European Association for Cranio-Maxillo-Facial Surgery"},{"key":"10.1016\/j.jbo.2012.12.001_bib62","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10103-009-0687-y","article-title":"Surgical approach with Er:YAG laser on osteonecrosis of the jaws (ONJ) in patients under bisphosphonate therapy (BPT)","volume":"25","author":"Vescovi","year":"2010","journal-title":"Lasers in Medical Science"},{"key":"10.1016\/j.jbo.2012.12.001_bib63","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.joms.2008.12.003","article-title":"Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws","volume":"67","author":"Freiberger","year":"2009","journal-title":"Journal of Oral and Maxillofacial Surgery: Official Journal of the American Association of Oral and Maxillofacial Surgeons"},{"key":"10.1016\/j.jbo.2012.12.001_bib64","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.tripleo.2010.05.067","article-title":"Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series","volume":"110","author":"Epstein","year":"2010","journal-title":"Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics"},{"key":"10.1016\/j.jbo.2012.12.001_bib65","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/scs.0b013e31857261f","article-title":"Ozone therapy in the treatment of avascular bisphosphonate-related jaw osteonecrosis","volume":"18","author":"Agrillo","year":"2007","journal-title":"The Journal of Craniofacial Surgery"},{"key":"10.1016\/j.jbo.2012.12.001_bib66","doi-asserted-by":"crossref","first-page":"72e","DOI":"10.1177\/030089161209800322","article-title":"Treatment of osteonecrosis of the jaw (ONJ) by medical ozone gas insufflation. A case report","volume":"98","author":"Ripamonti","year":"2012","journal-title":"Tumori"},{"key":"10.1016\/j.jbo.2012.12.001_bib67","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.oraloncology.2011.01.002","article-title":"Efficacy and safety of medical ozone (O(3)) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: Preliminary results of a phase I\u2013II study","volume":"47","author":"Ripamonti","year":"2011","journal-title":"Oral oncology"},{"key":"10.1016\/j.jbo.2012.12.001_bib68","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1005361","article-title":"Teriparatide and osseous regeneration in the oral cavity","volume":"363","author":"Bashutski","year":"2010","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jbo.2012.12.001_bib69","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.tripleo.2011.04.020","article-title":"A model for the pathogenesis of bisphosphonate-associated osteonecrosis of the jaw and teriparatide's potential role in its resolution","volume":"112","author":"Subramanian","year":"2011","journal-title":"Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics"},{"key":"10.1016\/j.jbo.2012.12.001_bib70","doi-asserted-by":"crossref","unstructured":"Narvaez J. Lack of response to teriparatide therapy for bisphosphonate-associated osteonecrosis of the jaw: reply to Subramanian and Quek. Osteoporosis International: A Journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2012.","DOI":"10.1007\/s00198-012-1996-8"},{"key":"10.1016\/j.jbo.2012.12.001_bib71","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.tripleo.2011.09.001","article-title":"Teriparatide's potential role in jaw bone related diseases","volume":"112","author":"Miller","year":"2011","journal-title":"Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics"},{"key":"10.1016\/j.jbo.2012.12.001_bib72","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1563\/1548-1336(2007)33[371:UOPPIT]2.0.CO;2","article-title":"Use of platelet-rich plasma in the management of oral biphosphonate-associated osteonecrosis of the jaw: a report of 2 cases","volume":"33","author":"Lee","year":"2007","journal-title":"The Journal of Oral Implantology"},{"key":"10.1016\/j.jbo.2012.12.001_bib73","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1200\/JCO.2010.32.5209","article-title":"American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer","volume":"29","author":"Van Poznak","year":"2011","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.jbo.2012.12.001_bib74","doi-asserted-by":"crossref","unstructured":"Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN, et al. NCCN task force report: bone health in cancer care. Journal of the National Comprehensive Cancer Network 2009;7 (Suppl. 3):S1\u201332; quiz S3\u20135.","DOI":"10.6004\/jnccn.2009.0076"},{"key":"10.1016\/j.jbo.2012.12.001_bib75","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","article-title":"American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma","volume":"20","author":"Berenson","year":"2002","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.jbo.2012.12.001_bib76","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1200\/JCO.2008.16.9300","article-title":"Natural history of osteonecrosis of the jaw in patients with multiple myeloma","volume":"26","author":"Badros","year":"2008","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.jbo.2012.12.001_bib77","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S8756-3282(01)00655-X","volume":"30","author":"Van Beek","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.jbo.2012.12.001_bib78","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.oraloncology.2009.01.002","article-title":"Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): a concise update","volume":"45","author":"Bagan","year":"2009","journal-title":"Oral Oncology"}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137412000474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137412000474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:16:15Z","timestamp":1761941775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137412000474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S2212137412000474"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2012.12.001","relation":{},"ISSN":["2212-1374"],"issn-type":[{"type":"print","value":"2212-1374"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral care and the use of bone-targeted agents in patients with metastatic cancers: A practical guide for dental surgeons and oncologists","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2012.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier GmbH.","name":"copyright","label":"Copyright"}]}}